In general, the difficulties in any evaluation of the treatment of depression can be related to the following factors:
1) The choice of drug (this affects the design of the study-i.e. whether it is controlled or uncontrolled, and if the former, controlled in what way);
2) The choice of patients (this involves an attempt to obtain homogeneity of the group which, in turn, relates to the difficulties in diagnosis in this area);
3) The choice of investigator (this involves the personality of the investigator [2, 3, 8] as a source of bias in treatment as well as in evaluation);
4) The choice of setting (5, 6, 8) (i.e. in-patient versus out-patient, [5] the choice of which is influenced by the ease with which these are available and also perhaps by economic factors).
What we propose to do here is to discuss each of these general points and then discuss how, in the last year, we have attempted to cope with these difficulties in an out-patient private practice setting. First, the choice of drug. This factor is important in that it determines the type of study to be carried out. Thus, if one is dealing with a completely new drug the obvious choice is a study aimed at giving a clinical feel for the drug, obtaining some idea of dosage range, and in addition obtaining some early toxicologic information; this, irrespective of the setting. Clearly, such an investigation cannot be a control study. It may be that after such an evaluative study the investigator will no longer be involved with the drug. In passing, one might ask what should be done with the data. We feel they should be published, but both the investigator and the reader should be well aware of the preliminary nature of the study, as it is no more valid to make extravagant claims at this time than it is to damn the study as worthless because it is 'uncontrolled'.
If the drug has already passed this early stage of investigation, then obviously a more controlled study is required, i.e, a comparison of the medication with a placebo (1, 4, (8) (9) (10) and/or a standard accepted preparation.
When we come to the choice of patient we come to the major difficulty in any study. The power of any investigation of therapeutic efficacy depends in large measure on the use of a homogeneous group of patients. There is always difficulty in achieving this latter, but the problem is exacerbated in studies of 'depression'. Unfortunately, the term 'depression' is used to describe a normal affect, a symptom, a syndrome and a diagnosis. (Further complications arise from controversies about depression as a diagnosis. Is there such a thing as pure or primary depression? Where does one place involutional depression? What is reactive depression? How long before reactive depression becomes chronic or psychotic? Should one really use the diagnosis of depression if depression as a symptom is not present? The latter problems are, however, outside the scope of this paper.)
To use a single treatment procedure when different conditions call for different therapies is bound to dilute the evidence of successful response. At times semantic confusion has led to the use of symptom-rating scales which dispense with diagnosis. Scaling is an amusing and admirable procedure, particularly in an age when the results can be subjected to high -speed data processing. Different types of depression can be factored out, numerous items can be scored in different ways on different tests, and items and scores can be differently programmed, all of which has resulted in the present variety of mathematically derived categories. The choose-as-you-like designations encourage do-as-you-like therapy, which in turn results in unnecessary therapeutic failures with drugs and the return to a type of treatment which does not recognize so much choice and decisioni.e. EST.
Confusion results from lumping together diseases which are quite disparate despite the fact that some of the same symptoms appear. For if we ignore diagnosis and treat only symptoms, we then ignore the natural history of the disease (7, 8) . Thus the results of certain clinical trials can be invalidated by the occurrence of natural remission or natural recurrence. Nor should the natural history of the drug effect itself be ignored since for most types of depression the shortterm trial is inadequate; evidence of improvement may not begin until the end of the first month of treatment. Thus there are many three-week trials of antidepressants which inevitably demonstrate that a drug is inactive when in point of fact it may be quite potent. Therefore at this stage we would urge a full consideration of the natural history of the illness as well as the natural history of the drug effect. This, without any attempts to define the former. We have stated elsewhere our belief in the retaining of diagnosis as an essential part of the progress of the treatment of depression. The imperfections of diagnosis are not to be improved by discarding what we already k?ow b~t by maintaining and improving diagnosis, The choice of investigator will not detain us too long, but undoubtedly, and this is extremely important for preliminary studies, the personality of the investigator (2, 3) in studies of depression is an important factor. This is not merely to say that some investigators can play their clinical hunches well, but it is to say that some people are better at treating depressions than are others. It is felt that this factor is minimized through use of controlled double-blind conditions.
The final factor to be discussed is the setting (5) (6) (7) . There are many obvious advantages to the in-patient treatment of depression, the major ones being complete control of the situation, continuous observation, and a reduced risk of suicide. This has to be weighed against the fear of hospital and the unpleasantly large gulf between conditions in private hospitals as compared with those in many state hospitals. These considerations, coupled with the fact that in most areas of North America hospitalization plans are not available, make the economic factor quite important. We mention this as, in many cases, it is assumed that out-patients must inevitably be less sick than in-patients and that the discharge rate from a hospital is a valid criterion of improvement. It would be of interest to note whether in countries with comprehensive medical care plans where no economic criteria pertain, patients may not remain hospitalized longer than they do in other situations; they certainly seem to be hospitalized more readily. Similarly, the situation where there is a limited insurance plan may lead to a patient's staying in hospital the full time of his insurance coverage, then being discharged irrespective of his degree of improvement. Leaving this aside, the advantage of out-patient treatment is that most people do not want to go into hospital; in a great many cases it is not necessary and so the patient may be treated in his home environment. Obviously there is much less control, the number of ratings are more limited and even the taking of the medication is left more to chance. Over the years these difficulties have in many cases led to a preponderance of clinical impression type of studies on out-patients, and indeed there are very few reports in the literature of attempts at controlled out-patient trials of antidepressants.
Related to all of the factors discussed above is the problem of instruments for continuous evaluation. The criteria for improvement are related to many factors. The clinical report may be valid in one situation but might not be valid in another (e.g. discharge, back to work). Thus it is definitely desirable to use a rating scale of symptom complexes which is standardized and which, in theory at least, allows more controlled and quantified comparative statements to be made with validity.
Having discussed four major factors and the related problem of measuring instruments, all of which contribute to the difficulties of rating the efficacy of drug treatments of depression, we shall now consider our practical attempt to deal with them. The last factor considered, that of setting presented no problem of choice. It did, however enter into several aspects of evaluation (5) and will be taken up wherever appropriate.
In an out-patient, private practice in 1964, where 325 new patients were seen, two-thirds of whom were suffering from depression, we have attempted to overcome the problems in a number of ways. Thus, some clinical procedures have been standardized.
On their first visits, all patients are weighed, have blood pressure readings standing and sitting recorded, and have blood and urine samples taken so that various tests (CBC, liver function tests, and urine analysis) can be carried out. These measurements are repeated at regular intervals on subsequent visits. Also on the first visit, a general purpose psychiatric questionnaire concerned with the patient's history is completed in part by the nurse and in part by the doctor. This form has been designed in such a way that the sociological and demographic data for the first pages can be obtained by the nurse, while the end pages, which pertain more to the illness, are completed by the doctor. (All the questions have been coded for SO-column computer cards, and we are about to start keypunching on the premises. It is hoped that this questionnaire will be used in other places, particularly in other count-ries, so that various factors relating to various illnesses can be studied. Sample forms are available on request.) The above procedures are common to all patients. The procedures following depend on the choice of drug.
If a study is being carried out on a new drug, obviously a blind study is inappropriate. But even at such an early stage in clinical drug evaluation it is desirable to have some degree of objectivity. Therefore, in these circumstances the patients are routinely diagnosed and evaluated independently by two of the authors, with one carrying out the treatment and . the other merely seeing the patients at the initial interview and at two and fourweek intervals. In this way a clinical feel for the drug and a notion of its 'natural history' are obtained. As has been mentioned earlier, psychiatric diagnosis provides the frame within which treatment effects can be evaluated. In connection with this, the use of two independent raters has shown itself to be an advantage inasmuch as it tends to make for more reliability and thoroughness. Also, at the end of the study it permits joint evaluation as well as evaluation of possible discrepancies between the raters. For example, using the APA classifications in a recent study of thirty-three patients suffering from 'depression' seen by the two authors mentioned above, there was complete agreement in diagnosis in twentyseven of the patients. For three patients disagreement consisted of qualifying phrases such as 'questionable schizophrenia', etc., and in three cases the diagnosis of psychotic depression was made by one investigator and psychoneurotic by the other. This is far from perfect, but on the other hand it illustrates quite well that sticking to standard classification and description does permit communication and replication in the vast majority of cases.
If the drug to be investigated is past the first stages of clinical evaluation, the situation calls for a controlled study wherein the drug will be compared to a placebo or, in most cases, to a standard preparation. Inasmuch as any controlled study is evaluated in terms of its rigorousness, certain stringencies must be observed, especially in an out-patient setting where large numbers of events are frequently unaccounted for and are beyond the control of the investigator.
Preliminary studies have suggested that an evaluating psychiatrist should not be involved in the choice of subjects for his study. Therefore, when a controlled study is under wayan independent psychiatrist sees all new patients, takes an intake history, makes a diagnosis, completes a rating scale, and at this stage decides whether the depressive element present is sufficient for inclusion in the study (i.e. the patients are suffering from psychotic, psychoneurotic, manic depressive or involutional depressions). His is the sole judgment as to borderline elements being present or not. Standard textbook diagnostic criteria are used and a certain homogeneity thus obtained. This psychiatrist plays no further part in the study.
Each patient to be included in the study is then seen separately by two of the writers who independently diagnose, evaluate, and rate the patient. One of these psychiatrists is the treating psychiatrist. In some studies he prescribes the specific medication to be taken by the patient; in others he knows only the general type of medication the patient will receive in accordance with a pre-determined random pattern (i.e. MAO inhibitor or tricyclic compound). The treating psychiatrist's knowledge of at least medication type is a clinical safeguard. If he were the only psychiatrist following the patient's progress there would be a possibility of bias entering into his ratings of the patient. Hence the evaluations made by the other evaluating psychiatrist who never has any knowledge of the medication prescribed. Indeed at the beginning of his interviews with patients he explains what his function is and that he will be in no way involved with treatment and that in fact, he does not want to discuss medication.
Typically these control studies are of four-weeks' duration with patients returning at weekly or fortnightly intervals. The evaluating psychiatrist rates the patients on each return visit and at the end of the study, while the treating psychiatrist independently rates the patients at the end of the study (sometimes he also sees and rates the patients after two weeks).
Considering the concern evidenced above for regular, independent, nonbiased ratings of the patients, it seems proper at this time to discuss the measuring instruments used in these evaluations. Though there are many rating instruments suitable, some seem too long for this type of study, and others present some difficulties owing to differential item weightings or to occasional discrete ratings of symptom complexes that are reasonably similar. Inasmuch as we are not at this point interested in synthesizing or factoring symptom complexes but are interested in comparative studies, we have developed a rather simple rating scale as illustrated here.
No.__ _ DATE
(1) Mood (0) Within normal limits.
(1) Reduced pleasure. Does not enjoy things but not actually depressed.
(2) Sad, depressed, dejected.
(3) Pervading gloom, depression without relief. (1) Diminished interest in friends, some self-neglect.
(2) Decrease of interest with loss of participation, marked self-neglect.
(3) Minimal participation.
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(3) Fatigue (Including work) (0) Within normal limits.
(1) Diminution in energy, that is, does not feel like working, mild difficulty thinking, does not feel like doing things as previously but manages to perform. (2) A great effort to do anything, with definite slowed up thinking and lessening in performance. (1) Self-reproachful.
(2) Self-condemnatory to the point of believing punishment is deserved.
(3) Delusions and/or hallucinations. (1) Over-reactive, restless, concerned.
(2) Tense, perspiring, apprehensive.
(3) Fearful, agitated.
It contains nine items, all of which pertain to depression and two of which (items 7 and 9) pertain also to anxiety. This rating scale has the immediate advantage of being a simple, brief scale with a four-point range of scoring for each item. Thus, scores of 0,1,2, and 3 are representative of, respectively, normal, mild, moderate, or marked severity. The descriptive statements following the numerical values serve merely as guide lines for the rater. Additionally, the type of sleeping difficulty, diurnal variation, and the mode of onset of the illness are all checked separately as parts of the scale. This permits investigation of these factors for purposes other than this paper. Preliminary work suggests some refinement of this scale, notably the subdivision of Item 8: there is no simple linear rela-tionship in degree of retardation among various body functions. Despite Item 8, though, the inter-rater correlation is good.
It is also apparent that if we separated patients into diagnostic categories, i.e. excluded secondary depressions or borderline cases, then the inter-rater correlation would be higher and certainly greater than 0.8. We now use this rating scale in all our studies. It is felt that the above represents a reasonable and comprehensive out-patient treatment regimen suitable for carrying out double-blind placebo studies (1, 4, (8) (9) (10) , or better still, double-blind comparative studies. For medico-legal reasons as well as others the actual use of a placebo in an out-patient setting would seem to be a hazardous one, though it should be pointed out that we have done them.
Indeed, we recently showed a placebo to be better than the test drug! This, as one might expect, was related to the side effects the drug produced, making the patient in many cases feel worse rather than improving. Placebo studies such as these are certainly of great value inasmuch as one gets an idea of the amount of placebo response to be expected in an illness such as this and in a setting such as ours. It is of interest that the above study consisted of three parts -a Phase I study, a further non-blind study on a group of 'resistant depressions', and a double-blind study -and the same percentage of patients were rated improved on all three occasions. This is a very comforting state of affairs and also suggests that however desirable there is nothing magical about the double-blind placebo controlled study provided one has an idea of the placebo response inherent to the situation.
In summary, difficulties in evaluating the effects of treatment on depression are in common with difficulties in evalu-ati~g therapeutic efficacy on any illness, related to variations in the designs of studies, the definition and selection of a relatively homogeneous sample of patients, the differential effects of the personalities of investigators, and the setting and circumstances of treatment. In the particular case of rating de~r~ssio~, superimposed on the general difficulties are the problems co?tributed by th~natu:al history of the disease and the diffi.cul~Ies in diagnosis. Nonetheless, some objective quantification of the amount of. depression is desirable. We have descnbed our standardized clinical procedures in an out-patient setting as an example of one means of approach to the total problem, and we have described our experience using a simple rating scale as a quantified measure of change. We have also noted the desirability of knowing the placebo effect to be expected in treating severe depression in a particular setting, as~h~s provides a proper background for clinically preferable controlled studies com-paring active medications with each other.
Resume
Les auteurs presentent leur visualisation d'un regime therapeutique pour les malades des cliniques externes en ce qu'ils considerent raisonnable et eclairant de faire les etudes comparatives du placebo et du double insu. Pour des raisons medico-legales et autres, les auteurs estiment que l'emploi reel d'un placebo dans un milieu de clinique externe expose a certains dangers nonobstant le fait qu'euxmemes y aient deja eu recours. lIs ont merne demontre, dans une etude, que le placebo etait preferable ala drogue d'epreuve, au moins du point de vue des effets secondaires. De plus, les etudes avec Vol. 11, 1966 un placebo donnent une idee de la quanrite des reponses de l'ordre psychogene qu'on peut s'attendre d'avoir dans une maladie et en milieux particuliers. Les auteurs resument les difficultes rencontrees dans l'evolution des effets therapeutiques propres aux maladies depressives et les rapportent a celles qu'on trouve dans n'importe quel etat psychiatrique et, ce sont: des variations dans l'organisation de l'investigation, les effers differentiels des personnalites des chercheurs, le milieu et les circonstances du traitement. Dans le cas de la depression, l'histoire naturelIe de la maladie et les difficultes d'un diagnostic precis s'y ajoutent. lIs decrivent leur procedure clinique de standardisation chez les patients en clinique externe comme etant un exemple d'une facon d'aborder le problerne global.
